Jay R. Luly Sells 5,142 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock

by · The Cerbat Gem

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock traded down $0.30 during midday trading on Tuesday, reaching $8.64. 429,363 shares of the company traded hands, compared to its average volume of 209,776. Enanta Pharmaceuticals, Inc. has a 12 month low of $7.58 and a 12 month high of $17.80. The business has a 50 day moving average of $10.51 and a two-hundred day moving average of $12.04. The firm has a market capitalization of $183.08 million, a price-to-earnings ratio of -1.58 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The firm had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Enanta Pharmaceuticals’s quarterly revenue was down 22.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.33) earnings per share. As a group, equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.81 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Barclays PLC increased its position in shares of Enanta Pharmaceuticals by 294.2% during the 3rd quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 20,478 shares during the last quarter. Geode Capital Management LLC increased its holdings in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after buying an additional 14,575 shares during the last quarter. Krensavage Asset Management LLC increased its holdings in Enanta Pharmaceuticals by 19.7% during the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after buying an additional 246,736 shares during the last quarter. Wellington Management Group LLP bought a new position in Enanta Pharmaceuticals in the third quarter worth approximately $360,000. Finally, State Street Corp boosted its stake in shares of Enanta Pharmaceuticals by 6.4% during the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after acquiring an additional 27,147 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ENTA shares. Robert W. Baird reduced their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. JMP Securities reissued a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Get Our Latest Research Report on Enanta Pharmaceuticals

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Featured Stories